NCT Number: NCT00002083
Intranasal Peptide T in the Treatment of Painful Peripheral Neuropathy of AIDS
To compare the effects of intranasal peptide T and placebo in the treatment of painful peripheral neuropathy associated with human immunodeficiency virus (HIV) infection.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
Univ of Miami School of Medicine, Miami, Florida, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patients must have:
- Documented HIV-1 infection.
- CD4 count < 500 cells/mm3.
- HIV-1-associated distal symmetrical polyneuropathy, with peripheral neuropathy present for at least 6 weeks prior to study entry.
- Pain severity of at least 8 on an analog scale.
- Prior zidovudine therapy for at least the previous 3 months (unless patient has shown intolerance to zidovudine).
Exclusion criteria
Co-existing Condition:
Patients with the following symptoms and conditions are excluded:
- Neuropathy due to any other cause besides HIV infection.
- Any symptom consistent with a new or active underlying opportunistic infection or malignancy that could interfere with the evaluation of neuropathy.
- Clinical evidence of new or active CNS disease, potentially from opportunistic infection or neoplasm resulting from HIV infections, that could interfere with the evaluation of neuropathy.
- Other CNS disease (e.g., myelopathy) that could complicate the evaluation of neuropathy.
- Active life-threatening illness other than AIDS.
Concurrent Medication:
Excluded:
- Dapsone.
- Hydralazine.
- Isoniazid (INH).
- Current use of tricyclic antidepressants, anticonvulsants, or clonidine unless the patient has used the drug without a change in dose for at least 3 months prior to study entry.
- Narcotics, unless the patient has been using them for at least 6 weeks prior to study entry.
Prior Medication:
Excluded:
- ddI or ddC in the past 8 weeks.
- Prior peptide T.
- Prior tricyclic antidepressants, anticonvulsants, or clonidine unless they have been used for at least 3 months without change in dose.
- Other investigational drugs within the past 30 days.
Required:
- Zidovudine (if intolerance not demonstrated).
Required:
- Zidovudine for at least the previous 3 months (unless patient has demonstrated intolerance to zidovudine).
Chronic alcohol abuse, or current abuse of psychoactive recreational drugs as defined in DSM IIIR. Patients who may be regarded as unreliable for the study.
Treatment and study plan
Sponsors and collaborators
Lead sponsor
Advanced Peptides
Industry
Registry information
Important dates
- First posted
- Aug 31, 2001
- Registry last updated
- Jun 24, 2005
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy
NCT00000842
AIDS-Related Complex, Acquired Immunodeficiency Syndrome
Los Angeles, California, United States
View Trial DetailsThe Efficacy of a Standardized Acupuncture Regimen and Amitriptyline Compared With Placebo as a Treatment for Pain Caused by Peripheral Neuropathy in HIV-Infected Patients
NCT00000817
AIDS-Related Complex, Acquired Immunodeficiency Syndrome
San Francisco, California, United States
View Trial DetailsA Phase II/III Double-Blind Study of Amitriptyline and Mexiletine for Painful Neuropathy in HIV Infection
NCT00000793
AIDS-Related Complex, Acquired Immunodeficiency Syndrome
Birmingham, Alabama, United States
View Trial DetailsAcupuncture/Moxibustion for Peripheral Neuropathy in HIV
NCT00317291
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
New York, United States
View Trial Details